Diseases : DID06067 - Fibroid

ZScoreRScoreEntity TypeIDNameSynonyms
2.45158020665 40 - [0, 0, 1, 3] Diseases DID06067 Fibroid Fibroid; Fibromyoma; Leiomyomatous Neoplasm; Leiomyoma; Fibromyomas; Leiomyomatous neoplasms; Fibroids; Fibroid Tumors; Fibroid Tumor; fibroid; Leiomyomas; Leiomyomatous Tumor; Leiomyoma nos (morphologic abnormality); Leiomyomatous neoplasm (morphologic abnormality); Leiomyomatous neoplasm nos (morphologic abnormality)
Back to View Results

RScore Document Snippets Details
40 - [0, 0, 1, 3] Bisphenol A, benzophenone-type ultraviolet filters, and phthalates in relation to uterine leiomyoma.
[MEDLINE : 25531814]
(2015) Bisphenol A, benzophenone-type ultraviolet filters, and phthalates in relation to uterine leiomyoma. Environmental research;Environ. Res.;2015 Feb;137:101-7

- There was a lack of an association between select nonpersistent chemicals and the odds of a fibroid diagnosis.

- Mono-methyl phthalate levels were significantly lower in women with than without fibroids (1.78µg/g vs. 2.40µg/g).

- Significantly higher geometric mean creatinine-corrected concentrations of BPA, 2,4OH-BP, and 2OH-4MeO-BP were observed in women with than without fibroids [BPA: 2.09µg/g vs. 1.46µg/g p=0.004; 2,4OH-BP:11.10µg/g vs. 6.71µg/g p=0.01; 2OH-4MeO-BP: 11.31µg/g vs. 6.10µg/g p=0.01].

- Urinary concentrations of bisphenol A (BPA), five benzophenone-type UV filters (2-hydroxy-4-methoxybenzophenone (2OH-4MeO-BP), 2,4-dihydroxybenzophenone (2,4OH-BP), 2,2׳-dihydroxybenzophenone (2,2׳OH-4MeO-BP), 2,2׳4,4׳-tetrahydroxybenzophenone (2,2׳4,4׳OH-BP), and 4-hydroxybenzophenone (4OH-BP), and 14 phthalate monoesters were quantified in 495 women who later underwent laparoscopy/laparotomy at 14 clinical sites for the diagnosis of fibroids.

Back to View Results

This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $900 million in funding from the federal government.